Generic Elepsia XR Availability
Last updated on May 7, 2025.
Elepsia XR is a brand name of levetiracetam, approved by the FDA in the following formulation(s):
ELEPSIA XR (levetiracetam - tablet, extended release;oral)
-
Manufacturer: TRIPOINT
Approval date: December 20, 2018
Strength(s): 1GM (discontinued) [RLD], 1.5GM (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elepsia XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral drug delivery system
Patent 8,163,306
Issued: April 24, 2012
Inventor(s): Dharmadhikari Nitin Bhalachandra & Zala Yashoraj Rupsinh & Singh Amarjit
Assignee(s): Sun Pharma Advanced Research CompanyAn oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
Patent expiration dates:
- September 3, 2027✓
- September 3, 2027
-
Pharmaceutical composition
Patent 8,425,938
Issued: April 23, 2013
Inventor(s): Zala Yashoraj Rupsinh & Dharmadhikari Nitin Bhalachandra
Assignee(s): Sun Pharma Advanced Research Company Ltd.The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
Patent expiration dates:
- February 22, 2026✓
- February 22, 2026
-
Pharmaceutical composition
Patent 8,431,156
Issued: April 30, 2013
Inventor(s): Zala Yashoraj Rupsinh & Dharmadhikari Nitin Bhalachandra
Assignee(s): Sun Pharma Advanced Research Company Ltd.The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
Patent expiration dates:
- October 31, 2027✓
- October 31, 2027
-
Oral drug delivery system
Patent 8,470,367
Issued: June 25, 2013
Inventor(s): Bhalachandra Dharmadhikari Nitin & Rupsinh Zala Yashoraj & Singh Amarjit
Assignee(s): Sun Pharma Advanced Research Company Ltd.An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating comprising water insoluble polymer(s) and leachable component(s) is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
Patent expiration dates:
- October 31, 2027✓
- October 31, 2027
-
Pharmaceutical composition
Patent 8,535,717
Issued: September 17, 2013
Inventor(s): Zala Yashoraj Rupsinh & Dharmadhikari Nitin Bhalachandra
Assignee(s): Sun Pharma Advanced Research Company LimitedThe present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
Patent expiration dates:
- February 22, 2026✓
- February 22, 2026
More about Elepsia XR (levetiracetam)
- Elepsia XR consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.